Morphic to Present at the Jefferies Global Healthcare Conference
06 Junho 2023 - 5:05PM
Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company
developing a new generation of oral integrin therapies for the
treatment of serious chronic diseases, today announced that its
management team will participate in the Jefferies Healthcare
Conference, including a hosted fireside chat, on Wednesday, June 7,
2023.
Fireside Chat InformationDate:
Wednesday June 7, 2023Time: 1:00 PM ETA live webcast of the
presentation will be available on the Investor section of the
Morphic website, or at the link here. An archived replay will be
available on the company’s website following the conference.
About Morphic
TherapeuticMorphic Therapeutic is a biopharmaceutical
company developing a portfolio of oral integrin therapies for the
treatment of serious chronic diseases, including autoimmune,
cardiovascular, and metabolic diseases, fibrosis, and cancer.
Morphic is also advancing its pipeline and discovery activities in
collaboration with Schrödinger using its proprietary MInT
technology platform which leverages the Company’s unique
understanding of integrin structure and biology. For more
information, visit www.morphictx.com.
ContactsMorphic
TherapeuticChris Erdmanchris.erdman@morphictx.com617.686.1718
Morphic (NASDAQ:MORF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Morphic (NASDAQ:MORF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024